Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Salestools Logo

Salestools

L'agent IA #1 pour les équipes de vente et Go-to-Market. Vendez plus, plus vite, avec moins d'effort.

Produit

  • Agents de vente IA
  • Données d'intention
  • Données technologiques
  • Suivi des visiteurs
  • Copilote
  • Vente sociale

Solutions

  • Service client
  • E-commerce
  • SaaS
  • Entreprise
  • Petite entreprise

Ressources

  • Le rapport
  • Documentation
  • Référence API
  • Centre d'aide
  • Blog
  • Études de cas
  • Webinaires

Entreprise

  • À propos
  • Carrières
  • Presse
  • Contact
  • Partenaires

Nos bureaux

  • New York, HQ
  • Bucarest, Laboratoire de recherche IA
  • Zug, Suisse

© 2025 Salestools. Tous droits réservés.

Conditions relatives aux données et sécuritéPolitique de confidentialitéConditions de service
Tous les systèmes opérationnels
Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Back to The Report
Biotech

Insitro

Insitro raises $400M Series D at $2.8B valuation

$400M
Total Raised
Series D
Latest Round
2018
Founded
300+
Employees
279 East Grand Avenue, South San Francisco, CA 94080
Updated September 8, 2024
1 min read

Quick Facts

Valuation
$2.8B
Latest Round Size
$400M
Latest Round Date
September 2024

Insitro: Series D Funding Round

Insitro has successfully raised $400M in Series D funding, reaching a valuation of $2.8B.

Company Overview

Machine learning for drug discovery

Funding Details

The Series D round was led by Blackstone, with participation from Canada Pension Plan Investment Board, Arch Venture Partners, Foresite Capital, GV, Andreessen Horowitz.

Company Information

  • Headquarters: 279 East Grand Avenue, South San Francisco, CA 94080
  • Founded: 2018
  • Employees: 300+
  • Category: Biotech

Investment

Insitro plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Blackstone: Verified investor in Series D
  • Canada Pension Plan Investment Board: Verified investor in Series D
  • Arch Venture Partners: Verified investor in Series D
  • Foresite Capital: Verified investor in Series D
  • GV: Verified investor in Series D
  • Andreessen Horowitz: Verified investor in Series D

Key Investors

Blackstone
Lead Investor
Verified investor in Series D
Canada Pension Plan Investment Board
Investor
Verified investor in Series D
Arch Venture Partners
Investor
Verified investor in Series D
Foresite Capital
Investor
Verified investor in Series D
GV
Investor
Verified investor in Series D
Andreessen Horowitz
Investor
Verified investor in Series D

Topics

verified(3079)real-funding(3079)insitrobiotechseries-d279-east-grand-avenue

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M